Disclaimer: This document provides comprehensive medical information for educational purposes and should not be considered a substitute for professional medical advice, diagnosis, or treatment. Clinical decisions must always be made by a qualified healthcare professional based on the individual patient's condition, medical history, and current clinical guidelines. This information is intended for clinicians and assumes a foundational understanding of medical principles.

---

Nephritic Syndrome

Overview

• Definition: Nephritic syndrome is a clinical constellation characterized by acute onset of glomerular inflammation and injury, leading to hematuria (often with dysmorphic red blood cells and red blood cell casts), varying degrees of proteinuria (typically non-nephrotic range, i.e., <3.5 g/24h, but can be higher), hypertension, edema (due to fluid retention), and acute kidney injury (AKI) with elevated serum creatinine and oliguria. The core pathological process is inflammation of the glomeruli, which disrupts the glomerular basement membrane and allows blood cells to pass into the urine.

• Epidemiology:

  • The overall incidence varies widely depending on the specific cause of glomerulonephritis (GN).
  • Post-Streptococcal Glomerulonephritis (PSGN): Most common cause of acute nephritic syndrome in children aged 2-12 years. Incidence has decreased in developed countries due to improved hygiene and antibiotic use but remains significant in developing regions.
  • IgA Nephropathy (Berger's Disease): The most common primary glomerulonephritis worldwide, affecting individuals of all ages but often peaking in young adults (2nd-3rd decade). Males are more commonly affected than females.
  • Rapidly Progressive Glomerulonephritis (RPGN): Less common but highly aggressive, often affecting older adults. Its incidence varies based on the underlying etiology (e.g., ANCA-associated vasculitis more common in older adults, anti-GBM disease more common in young adults and older adults).
  • Lupus Nephritis: Affects up to 60% of patients with Systemic Lupus Erythematosus (SLE), with a higher prevalence in women and certain ethnic groups (e.g., African Americans, Hispanics).

• Classification: Nephritic syndrome is a clinical presentation, not a single disease. It is classified based on the underlying histopathological diagnosis of glomerulonephritis, which can be:

  • Primary Glomerulonephritis: Disease primarily affecting the kidney, with no identifiable systemic cause.
    • Post-Streptococcal Glomerulonephritis (PSGN)
    • IgA Nephropathy
    • Membranoproliferative Glomerulonephritis (MPGN) – now often reclassified based on complement pathway activation (e.g., C3 glomerulopathy)
    • Rapidly Progressive Glomerulonephritis (RPGN) – often a clinical syndrome with varied histologies (e.g., anti-GBM, immune complex, pauci-immune)
  • Secondary Glomerulonephritis: Glomerular disease occurring as part of a systemic disorder.
    • Systemic Lupus Erythematosus (SLE) – Lupus Nephritis (various classes)
    • ANCA-associated Vasculitides (Granulomatosis with Polyangiitis, Microscopic Polyangiitis, Eosinophilic Granulomatosis with Polyangiitis)
    • Anti-Glomerular Basement Membrane (Anti-GBM) Disease (Goodpasture Syndrome if associated with pulmonary hemorrhage)
    • Cryoglobulinemic Vasculitis (often associated with Hepatitis C infection)
    • Infection-related Glomerulonephritis (e.g., endocarditis, shunt nephritis, Hepatitis B/C associated)
    • Henoch-Schönlein Purpura (IgA Vasculitis) – a systemic form of IgA nephropathy
    • Other systemic diseases: Scleroderma, polyarteritis nodosa, sarcoidosis, amyloidosis (can rarely present with nephritic features, though more often nephrotic).

Pathophysiology

• Mechanism: The underlying mechanism of nephritic syndrome involves immune-mediated injury to the glomeruli, leading to inflammation and damage to the glomerular capillary wall. This damage increases permeability, allowing red blood cells and protein to leak into the urine, and also reduces the glomerular filtration rate (GFR). Key mechanisms include:

  • Immune Complex Deposition:
    • In situ immune complex formation: Antibodies react with antigens planted within the glomerulus (e.g., anti-GBM disease, some forms of MPGN).
    • Circulating immune complex deposition: Immune complexes formed in the circulation are trapped in the glomeruli (e.g., PSGN, IgA nephropathy, Lupus Nephritis, cryoglobulinemic GN). These complexes activate complement and recruit inflammatory cells (neutrophils, macrophages, T cells), leading to release of cytokines, proteases, and reactive oxygen species, causing direct injury to glomerular cells and matrix.
  • Anti-Glomerular Basement Membrane (Anti-GBM) Antibodies: Autoantibodies directly target components of the glomerular basement membrane (GBM), primarily the alpha-3 chain of Type IV collagen. This leads to severe inflammation, often with linear deposition of IgG on immunofluorescence and rapidly progressive disease.
  • Pauci-Immune Glomerulonephritis: Characterized by little or no immune complex deposition on immunofluorescence. This form is strongly associated with circulating anti-neutrophil cytoplasmic antibodies (ANCAs), which activate neutrophils to degranulate and cause endothelial damage in small vessels, including glomerular capillaries (e.g., Granulomatosis with Polyangiitis, Microscopic Polyangiitis).
  • Cell-mediated Immunity: T-cell mediated injury can also play a role in some forms of GN, contributing to the inflammatory cascade and crescent formation.
  • Consequences of Glomerular Injury:
    • Hematuria: Disruption of the glomerular basement membrane allows red blood cells to pass. Dysmorphic RBCs and RBC casts indicate a glomerular origin.
    • Proteinuria: Increased permeability of the glomerular filtration barrier. Typically non-nephrotic, but can be higher, especially in mixed presentations or severe cases.
    • Decreased GFR: Inflammatory cell infiltration, swelling of glomerular capillaries, and crescent formation reduce the filtration surface area and blood flow, leading to AKI.
    • Hypertension: Due to fluid retention (reduced GFR, sodium reabsorption) and activation of the renin-angiotensin-aldosterone system.
    • Edema: Primarily due to sodium and water retention from reduced GFR and increased tubular reabsorption.

• Risk Factors:

  • Infections:
    • Streptococcal infections (Group A beta-hemolytic strep, pharyngitis, impetigo) for PSGN.
    • Other bacterial infections (endocarditis, shunt infections).
    • Viral infections (Hepatitis B, Hepatitis C, HIV, EBV, CMV).
  • Autoimmune Diseases: Systemic Lupus Erythematosus (SLE), rheumatoid arthritis, inflammatory bowel disease, sarcoidosis.
  • Genetic Predisposition: Certain HLA types are associated with increased risk for some ANCA-associated vasculitides, IgA nephropathy, and SLE. Complement pathway abnormalities can predispose to C3 glomerulopathy.
  • Environmental Factors: Exposure to certain drugs (e.g., hydralazine, propylthiouracil associated with ANCA-positive vasculitis; penicillamine), silica dust (associated with ANCA-positive vasculitis).
  • Age: PSGN is more common in children; ANCA-associated vasculitis and anti-GBM disease are more common in older adults.

• Protective Factors:

  • Prompt treatment of infections: Especially streptococcal infections, although this does not reliably prevent PSGN.
  • Vaccinations: Routine vaccinations (e.g., against influenza, pneumococcus) can reduce the risk of infections that might trigger immune responses.
  • Good control of underlying autoimmune diseases: Adherence to treatment regimens for SLE or other systemic conditions can reduce the risk or severity of renal involvement.
  • Healthy lifestyle: General measures like maintaining a healthy immune system, although direct "protective" factors against the specific immune dysregulation leading to nephritic syndrome are limited.

Clinical Presentation

Signs and Symptoms

• Cardinal Features:

  • Hematuria: Gross (cola-colored, tea-colored, smoky urine) or microscopic. Often the presenting symptom.
  • Oliguria: Reduced urine output (<400-500 mL/24h in adults).
  • Hypertension: Elevated blood pressure, often mild to moderate but can be severe.
  • Edema: Periorbital (especially in children), facial, and dependent peripheral edema (ankles, sacrum).
  • Acute Kidney Injury (AKI): Rapid decline in GFR, leading to elevated serum creatinine and blood urea nitrogen (BUN).

• Early Signs:

  • Subtle changes in urine color.
  • Mild, often transient, edema.
  • Non-specific symptoms like fatigue, malaise, headache, anorexia.
  • Mild elevation in blood pressure.

• Advanced Signs: (Indicating more severe or rapidly progressive disease)

  • Severe Oliguria/Anuria: Markedly reduced or absent urine output.
  • Severe Hypertension: Hypertensive crisis, potentially leading to encephalopathy, seizures, or heart failure.
  • Signs of Fluid Overload: Dyspnea, orthopnea, pulmonary crackles (rales), jugular venous distension (JVD) due to congestive heart failure.
  • Uremic Symptoms: Nausea, vomiting, confusion, asterixis, pericarditis, pleuritis, pruritus (indicating severe AKI and accumulation of toxins).
  • Systemic manifestations of underlying disease (e.g., rash, arthralgia/arthritis, fever, pleurisy, serositis in SLE; purpura, abdominal pain, arthralgia in IgA vasculitis; hemoptysis in Goodpasture syndrome or ANCA-associated vasculitis).

• Atypical Presentations:

  • Isolated microscopic hematuria: Without other features of nephritic syndrome (e.g., early IgA nephropathy, Alport syndrome).
  • Isolated hypertension: With mild, unrecognized renal dysfunction.
  • Nephrotic range proteinuria: Can occur in severe cases or in forms with mixed features (e.g., severe IgA nephropathy, some MPGN, Lupus Nephritis Classes III/IV, collapsing glomerulopathy).
  • Absence of overt edema or hypertension: If renal injury is mild.

Physical Examination

• Inspection:

  • Edema: Facial (especially periorbital), sacral, lower extremity pitting edema.
  • Skin: Rashes (malar rash in SLE, palpable purpura in IgA vasculitis/cryoglobulinemia, livedo reticularis), petechiae, splinter hemorrhages.
  • Signs of Fluid Overload: Distended neck veins (JVD), increased respiratory rate, labored breathing.
  • Pallor: Due to anemia (chronic kidney disease or rapid decline in renal function).

• Palpation:

  • Pitting Edema: Assess severity and extent.
  • Abdomen: Ascites (if severe fluid overload).
  • Joints: Tenderness or swelling (arthritis in SLE, IgA vasculitis).

• Special Tests:

  • Blood Pressure Measurement: Crucial for diagnosis and monitoring; often elevated.
  • Cardiopulmonary Auscultation:
    • Lungs: Crackles (rales) at lung bases indicating pulmonary edema.
    • Heart: S3 gallop indicating heart failure, pericardial rub if uremic pericarditis.
  • Fundoscopy: To assess for hypertensive retinopathy (arteriolar narrowing, hemorrhages, papilledema) in severe hypertension.

Diagnostic Approach

History Taking

• Key Questions:

  • Timing and Onset: Acute or insidious onset of symptoms? (Rapidly progressive points to RPGN).
  • Recent Infections: History of sore throat, skin infection (impetigo) 1-3 weeks prior (PSGN)? Recent viral illness?
  • Systemic Symptoms: Fever, weight loss, night sweats, arthralgias, myalgias, rash, oral ulcers, photosensitivity (SLE)? Recurrent sinusitis, epistaxis, hemoptysis, chronic cough (ANCA vasculitis, Goodpasture)? Abdominal pain, joint pain (IgA vasculitis, cryoglobulinemia)?
  • Medication History: New medications, over-the-counter drugs, herbal supplements.
  • Past Medical History: Known autoimmune diseases (SLE, RA), Hepatitis B/C, HIV, diabetes, hypertension.
  • Family History: Kidney disease, deafness, visual disturbances (Alport syndrome)? Autoimmune diseases?
  • Travel History: Exposure to endemic infections.
  • Urine Characteristics: Color (dark, smoky, red), clarity, foaminess (suggests heavy proteinuria).
  • Fluid Status: Swelling location and progression, urine output changes.

• Red Flags: (Require urgent evaluation and often immediate intervention)

  • Rapidly Progressive Symptoms: Worsening renal function over days to weeks (suggests RPGN).
  • Severe Hypertension: Especially with neurological symptoms (headache, confusion, seizures) or pulmonary edema.
  • Anuria/Severe Oliguria: Suggests severe AKI requiring urgent intervention, potentially dialysis.
  • Hemoptysis: Suggests pulmonary-renal syndrome (e.g., Goodpasture, ANCA vasculitis, SLE).
  • Uremic Symptoms: Nausea, vomiting, altered mental status, pericarditis.

Laboratory Tests

• First-Line:

  • Urinalysis with Microscopy:
    • Hematuria: Presence of red blood cells; >5 RBCs/HPF is significant.
    • Dysmorphic RBCs: Irregularly shaped RBCs, suggestive of glomerular origin.
    • Red Blood Cell Casts: Pathognomonic for glomerulonephritis.
    • Proteinuria: Quantify using urine protein-creatinine ratio (UPCR) or 24-hour urine collection. Typically non-nephrotic (<3.5 g/day or UPCR <3.5 mg/mg), but can be higher.
    • Leukocyturia/white cell casts: Can be present due to inflammation.
  • Serum Creatinine (Cr) and Blood Urea Nitrogen (BUN): To assess renal function and severity of AKI.
  • Electrolytes (Na, K, Cl, HCO3): To check for hyperkalemia, metabolic acidosis, and other imbalances due to AKI.
  • Complete Blood Count (CBC): May show anemia (dilutional, chronic kidney disease, or associated with systemic disease) and leukocytosis (inflammation/infection).

• Confirmatory: (To determine the underlying cause)

  • Complement Levels (C3, C4, CH50):
    • Low C3 and C4: Suggests classical complement pathway activation (e.g., SLE, cryoglobulinemia, some MPGN).
    • Low C3 only: Suggests alternative pathway activation (e.g., PSGN, C3 glomerulopathy).
    • Normal C3 and C4: Common in IgA nephropathy, ANCA-associated vasculitis, anti-GBM disease.
  • Serologic Tests for Infections:
    • Anti-Streptolysin O (ASO) titer and Anti-DNase B titer: For PSGN (elevated ASO >200 Todd units, Anti-DNase B more sensitive for skin infections).
    • Hepatitis B (HBsAg, anti-HBs, anti-HBc) and Hepatitis C (anti-HCV, HCV RNA): For infection-related GN, cryoglobulinemia.
    • HIV testing: If clinically indicated.
  • Autoantibody Panel:
    • Antinuclear Antibodies (ANA) and anti-dsDNA: For Systemic Lupus Erythematosus (SLE).
    • Anti-Neutrophil Cytoplasmic Antibodies (ANCA):
      • c-ANCA (anti-PR3): Strong association with Granulomatosis with Polyangiitis (GPA).
      • p-ANCA (anti-MPO): Strong association with Microscopic Polyangiitis (MPA) and Eosinophilic Granulomatosis with Polyangiitis (EGPA).
    • Anti-Glomerular Basement Membrane (Anti-GBM) Antibodies: For anti-GBM disease.
  • Cryoglobulins: For cryoglobulinemic vasculitis.
  • Serum Protein Electrophoresis (SPEP) and Urine Protein Electrophoresis (UPEP): To rule out monoclonal gammopathy, which can be associated with some forms of GN.
  • Kidney Biopsy: Gold standard for definitive diagnosis, determining the specific type of glomerulonephritis, assessing disease activity and chronicity, and guiding treatment. Should be considered in all cases of suspected glomerulonephritis unless a clear diagnosis can be made clinically (e.g., classic PSGN with improving renal function) or contraindications exist.
    • Indications: Suspected RPGN, uncertain diagnosis, persistent proteinuria/hematuria, unexplained AKI, suspicion of systemic disease.

• Monitoring:

  • Daily/Frequent (in acute phase): Serum Cr, BUN, electrolytes, urine output, blood pressure.
  • Weekly/Bi-weekly (during initial treatment): Serum Cr, BUN, electrolytes, CBC (if on immunosuppression), liver function tests (if on certain medications).
  • Monthly/Quarterly (in chronic phase): Serum Cr, BUN, electrolytes, urinalysis, urine protein-creatinine ratio, CBC, BP, serologic markers (e.g., ANA, ANCA, complement) as appropriate for the underlying disease.

Imaging

• Recommended:

  • Renal Ultrasound:
    • Purpose: To assess kidney size, cortical echogenicity (reflects chronicity), and rule out obstructive uropathy as a cause of AKI. Small, echogenic kidneys suggest chronic kidney disease. Normal or enlarged kidneys are common in acute glomerulonephritis.
    • Findings: May show normal or enlarged kidneys with increased cortical echogenicity. Hydronephrosis should be absent.

• Advanced:

  • Chest X-ray (CXR): If pulmonary symptoms (dyspnea, hemoptysis) or fluid overload are present. May show pulmonary edema, infiltrates (hemorrhage in Goodpasture or ANCA-associated vasculitis).
  • CT or MRI of Chest/Abdomen/Brain: If systemic vasculitis is suspected with involvement of other organs (e.g., sinus disease, lung nodules, brain lesions in GPA). Not routinely performed solely for nephritic syndrome.

Management

Acute Management

• Immediate: (Focus on life-threatening complications)

  • Blood Pressure Control: Initiate antihypertensive therapy if BP is elevated. Target BP typically <140/90 mmHg, but may need to be lower (e.g., <130/80 mmHg in CKD with proteinuria). Calcium channel blockers (e.g., amlodipine) or loop diuretics (e.g., furosemide) are often first-line, especially in the setting of volume overload. ACE inhibitors/ARBs are renoprotective but might be used cautiously in acute AKI due to hyperkalemia risk.
  • Fluid Restriction: For patients with edema or fluid overload, restrict oral fluid intake to insensible losses + urine output.
  • Diuretics: Loop diuretics (e.g., furosemide 20-80 mg IV/PO, titrated) to manage fluid overload, edema, and contribute to BP control.

• Stabilization:

  • Electrolyte Management: Correct hyperkalemia (e.g., calcium gluconate for cardiac stability, insulin-glucose, kayexalate) and metabolic acidosis (e.g., sodium bicarbonate).
  • Management of AKI: Monitor urine output and renal function closely. Avoid nephrotoxic agents.
  • Preparation for Renal Biopsy: If indicated, stabilize patient prior to biopsy.

• Emergency: (For severe cases, especially RPGN)

  • Renal Replacement Therapy (RRT): Hemodialysis or peritoneal dialysis may be required for indications such as severe uremia (encephalopathy, pericarditis), intractable fluid overload, severe hyperkalemia, or severe metabolic acidosis unresponsive to medical therapy.
  • High-Dose Glucocorticoids:
    • Methylprednisolone pulse therapy: Often used in RPGN (anti-GBM, ANCA-associated, severe lupus nephritis) to rapidly suppress inflammation. Typical dose: 500 mg to 1 g IV daily for 3-5 days.
  • Plasmapheresis (Plasma Exchange):
    • Indications: Anti-GBM disease (especially with pulmonary hemorrhage or severe renal dysfunction), severe ANCA-associated vasculitis with diffuse alveolar hemorrhage or rapidly worsening renal function, severe cryoglobulinemic vasculitis.
    • Mechanism: Removes pathogenic antibodies (e.g., anti-GBM, ANCAs) and immune complexes from the circulation.

Chronic Management

• Pharmacological: Tailored to the specific underlying cause of glomerulonephritis.

  • Immunosuppression:
    • Corticosteroids: Oral prednisone (e.g., 0.5-1 mg/kg/day initially, tapered over months) is a cornerstone for most immune-mediated GNs (Lupus Nephritis, IgA nephropathy with severe features, ANCA-associated vasculitis, anti-GBM disease).
    • Cyclophosphamide: Potent immunosuppressant, often used in combination with steroids for induction therapy in severe RPGN (ANCA-associated, severe lupus nephritis). Dose: Oral 1.5-2.5 mg/kg/day or IV pulse 0.5-1 g/m² body surface area monthly. Monitor for bone marrow suppression and hemorrhagic cystitis.
    • Rituximab: Anti-CD20 monoclonal antibody. Used for induction and maintenance in ANCA-associated vasculitis, and in some cases of lupus nephritis, often as an alternative to cyclophosphamide or for refractory disease. Dose: 375 mg/m² weekly for 4 weeks (similar to lymphoma protocol) or 1 g IV on days 1 and 15 (vasculitis protocol).
    • Mycophenolate Mofetil (MMF): Used for maintenance therapy in ANCA-associated vasculitis, and as induction/maintenance in lupus nephritis. Dose: 1-1.5 g PO BID.
    • Azathioprine: Used for maintenance therapy in ANCA-associated vasculitis and lupus nephritis. Dose: 1-2 mg/kg/day.
    • Calcineurin Inhibitors (e.g., Tacrolimus, Cyclosporine): Used in some forms of lupus nephritis (especially membranous), focal segmental glomerulosclerosis, or as steroid-sparing agents.
  • Renoprotective Agents:
    • ACE Inhibitors or Angiotensin Receptor Blockers (ARBs): Indicated for proteinuria (>0.5 g/day) and hypertension, even if not nephritic in nature. They reduce intraglomerular pressure and proteinuria. Titrate slowly and monitor for hyperkalemia and AKI. Target BP typically <130/80 mmHg with proteinuria.

• Non-pharmacological:

  • Dietary Modifications:
    • Sodium restriction: <2 g/day to help control hypertension and edema.
    • Fluid restriction: As needed for fluid overload.
    • Protein intake: Moderate protein intake (0.8-1.0 g/kg/day) in non-dialysis CKD.
    • Potassium/Phosphate restriction: If hyperkalemia or hyperphosphatemia develop due to CKD.
  • Lifestyle Modifications:
    • Regular physical activity: As tolerated.
    • Smoking cessation: Crucial for kidney health.
    • Weight management: Maintain a healthy BMI.
  • Monitoring Blood Pressure at Home: Empower patients to track their BP.
  • Vaccinations: Ensure up-to-date vaccinations, especially for patients on immunosuppressants (e.g., influenza, pneumococcal, Hepatitis B, COVID-19). Live vaccines generally contraindicated during significant immunosuppression.

• Monitoring:

  • Regular Clinic Visits: Frequency depends on disease activity and stability (e.g., every 1-3 months initially, then every 3-6 months for stable patients).
  • Blood Pressure Monitoring: At every visit and home monitoring.
  • Renal Function: Serum creatinine, BUN, eGFR.
  • Urinalysis and Urine Protein/Creatinine Ratio: To assess hematuria and proteinuria trends.
  • Electrolytes: To monitor for imbalances and medication side effects.
  • CBC, LFTs: To monitor for side effects of immunosuppressive medications.
  • Specific Serologies: Depending on the cause (e.g., complement levels, anti-dsDNA in SLE; ANCA titers in ANCA-vasculitis, though not routinely for disease activity).
  • Imaging: Repeat renal ultrasound if renal function declines or to monitor for progression of CKD.

Treatment Algorithms

• General Principles:

  1. Rule out treatable causes: Such as infection or drug-induced.
  2. Confirm diagnosis with kidney biopsy: Essential for precise diagnosis and guiding therapy, especially for severe or progressive disease.
  3. Initiate supportive care: BP control, fluid management, electrolyte correction.
  4. Administer specific immunosuppressive therapy: Based on biopsy findings and underlying cause.

• First-Line:

  • Post-Streptococcal GN: Primarily supportive care (BP control, diuretics for fluid overload). Antibiotics only for active infection, not to prevent or treat established PSGN. Immunosuppression is generally not indicated.
  • IgA Nephropathy:
    • Low risk (isolated microscopic hematuria, proteinuria <0.5g/day, normal GFR): Observe, BP control with ACEi/ARB if BP >130/80 mmHg.
    • High risk (proteinuria >1g/day, progressive decline in GFR, severe histological features): Consider oral corticosteroids (e.g., prednisone 0.5-1 mg/kg/day for 6-9 months, or IV pulse methylprednisolone followed by oral taper) in conjunction with ACEi/ARB.
  • Lupus Nephritis (Proliferative classes III, IV, V with active features):
    • Induction: High-dose corticosteroids (e.g., methylprednisolone pulse 500-1000 mg IV daily for 3 days, then oral prednisone 0.5-1 mg/kg/day) plus cyclophosphamide (IV monthly pulses for 6 months) OR mycophenolate mofetil (MMF 1-1.5g BID for 6 months).
    • Maintenance: MMF (1-1.5g BID) or azathioprine (1.5-2 mg/kg/day) for several years.
  • ANCA-associated Vasculitis:
    • Induction: High-dose corticosteroids (methylprednisolone pulse, then oral prednisone) plus cyclophosphamide (oral or IV monthly pulses) OR rituximab.
    • Maintenance: Azathioprine, MMF, or rituximab.
  • Anti-GBM Disease: High-dose corticosteroids + cyclophosphamide + plasmapheresis. Treatment should be initiated urgently.

• Second-Line: (For cases unresponsive to first-line or with significant side effects)

  • IgA Nephropathy: Immunosuppression with rituximab or calcineurin inhibitors may be considered in selected cases, especially with persistent proteinuria despite maximal supportive care and steroids.
  • Lupus Nephritis: If initial induction fails, consider switching between cyclophosphamide and MMF, or adding/switching to calcineurin inhibitors, or rituximab.
  • ANCA-associated Vasculitis: Switching between cyclophosphamide and rituximab, or addition of IVIG in very refractory cases.
  • Other Immunosuppressants: Azathioprine, cyclosporine, tacrolimus, voclosporin (for lupus nephritis) or novel agents might be used depending on specific guidelines and patient profile.

• Refractory Cases:

  • Re-biopsy to assess disease activity vs. chronicity.
  • Intensification of immunosuppression (e.g., higher doses, combination therapy).
  • Consider alternative agents (e.g., IVIG, eculizumab for C3 glomerulopathy, novel agents in clinical trials).
  • Ultimately, progression to end-stage kidney disease may necessitate chronic dialysis or kidney transplantation. Recurrence in transplant may occur for certain GNs (e.g., IgA nephropathy, anti-GBM disease, C3 glomerulopathy).

Complications

• Common:

  • Hypertension: Can be acute and severe, or chronic.
  • Fluid Overload: Leading to edema, pulmonary edema, and congestive heart failure.
  • Acute Kidney Injury (AKI): Ranging from mild elevation in creatinine to severe requiring dialysis.
  • Electrolyte Imbalances: Hyperkalemia, metabolic acidosis.
  • Anemia: Due to fluid overload (dilutional), chronic kidney disease (decreased erythropoietin), or associated with systemic disease.
  • Infections: Due to immunosuppressive therapy.

• Serious:

  • End-Stage Kidney Disease (ESKD): Irreversible kidney failure requiring dialysis or transplantation. This is the most feared long-term complication, particularly with RPGN.
  • Hypertensive Emergencies: Malignant hypertension, hypertensive encephalopathy, intracranial hemorrhage.
  • Pulmonary Hemorrhage: Especially in Goodpasture Syndrome or ANCA-associated vasculitis (pulmonary-renal syndrome).
  • Severe Electrolyte Abnormalities: Life-threatening hyperkalemia, severe acidosis.
  • Cardiovascular Disease: Accelerated atherosclerosis due to CKD, hypertension, and inflammation.
  • Uremic Complications: Pericarditis, pleuritis, encephalopathy.
  • Opportunistic Infections: Due to immunosuppression (e.g., Pneumocystis pneumonia, viral reactivations).

• Long-term:

  • Chronic Kidney Disease (CKD): Progressive decline in renal function.
  • Requirement for Dialysis or Kidney Transplantation.
  • Increased Cardiovascular Morbidity and Mortality.
  • Side effects of immunosuppression: Increased risk of infections, malignancies, osteoporosis, diabetes, cataracts, avascular necrosis.
  • Recurrence of glomerulonephritis in native kidneys or kidney transplant.

Prognosis

• Factors: The prognosis of nephritic syndrome is highly variable and depends significantly on:

  • Underlying Histological Type of Glomerulonephritis:
    • PSGN: Generally excellent prognosis, with most children recovering full renal function. Adults may have a higher risk of residual proteinuria/hypertension or CKD.
    • IgA Nephropathy: Highly variable. About 20-30% of patients progress to ESKD over 10-20 years. Prognostic indicators include persistent proteinuria (>1g/day), hypertension, elevated serum creatinine at presentation, and severe histological features (e.g., crescents, fibrosis, tubular atrophy).
    • RPGN (Crescentic GN): Historically poor prognosis, but with aggressive immunosuppression, outcomes have improved. Prognostic factors include severity of AKI at presentation, percentage of crescents on biopsy (especially fibrous crescents), presence of interstitial fibrosis, and age. Early diagnosis and treatment are critical.
    • Lupus Nephritis: Prognosis has significantly improved with modern immunosuppression. However, active disease or progression to ESKD remains a major concern in a subset of patients.
  • Severity of Renal Dysfunction at Presentation: Higher creatinine, lower GFR, and presence of oliguria/anuria are poor prognostic indicators.
  • Presence and Extent of Crescents on Biopsy: Higher percentage of crescents (especially cellular and fibrocellular) generally indicates more aggressive disease and worse prognosis.
  • Degree of Interstitial Fibrosis and Tubular Atrophy: Reflects chronic damage and is a strong predictor of progression to CKD.
  • Age of Patient: Very young and elderly patients may have poorer outcomes.
  • Response to Treatment: Early and sustained remission of disease activity predicts better long-term outcomes.
  • Control of Associated Complications: Effective management of hypertension, proteinuria, and fluid overload.

• Survival:

  • PSGN: Very low mortality rate.
  • IgA Nephropathy: Long-term survival is good, but a significant proportion will develop ESKD.
  • RPGN: Untreated, leads to ESKD in most patients within months. With aggressive treatment, 5-year renal survival rates can be 50-80%, and patient survival rates are also significantly improved, but risk of relapse and treatment-related complications remain.
  • Lupus Nephritis: 10-year renal survival rates for treated proliferative lupus nephritis are generally >80%.

• Quality of Life:

  • Can be significantly impacted by chronic kidney disease, need for dialysis, side effects of immunosuppressive medications, and the burden of living with a chronic illness.
  • Early diagnosis and effective management aim to preserve renal function and minimize the need for RRT, thereby improving quality of life.

Prevention

• Primary: (Preventing the initial occurrence of glomerulonephritis)

  • Prompt treatment of Group A Streptococcal infections: While antibiotics for pharyngitis can prevent acute rheumatic fever, their effectiveness in preventing PSGN is less clear if initiated late after infection.
  • Vaccination: Routine childhood vaccinations. General hygiene to prevent skin infections.
  • Avoidance of risk factors: For some forms, avoiding certain drug exposures.

• Secondary: (Early detection and intervention to prevent progression or reduce severity)

  • Screening: For individuals at risk (e.g., patients with SLE, Hepatitis C).
  • Early Diagnosis: Prompt evaluation of hematuria, proteinuria, or unexplained AKI.
  • Kidney Biopsy: Early biopsy in cases of suspected RPGN or unexplained progressive renal dysfunction can lead to timely diagnosis and initiation of specific therapy, significantly impacting prognosis.
  • Aggressive management of underlying systemic diseases: E.g., maintaining remission in SLE.

• Tertiary: (Preventing complications and progression of established kidney disease)

  • Strict Blood Pressure Control: Using ACE inhibitors/ARBs for renoprotection and BP control. Target <130/80 mmHg with proteinuria.
  • Proteinuria Reduction: Maximizing use of ACE inhibitors/ARBs, and specific immunosuppression.
  • Management of CKD complications: Anemia, bone mineral disorders, metabolic acidosis, hyperkalemia.
  • Patient Education: On disease, medications, diet, and monitoring.
  • Regular Follow-up: With a nephrologist to monitor kidney function and manage comorbidities.

Special Populations

• Pediatric:

  • PSGN: Most common cause in children. Prognosis generally excellent. Management is primarily supportive.
  • IgA Nephropathy: Can be aggressive in children.
  • Lupus Nephritis: Often more severe at presentation in pediatric patients.
  • Genetic Glomerulonephritis: Alport syndrome should be considered in children with persistent hematuria, especially with family history of kidney disease or hearing loss.
  • Treatment Challenges: Dosing of medications, adherence issues, impact on growth and development.

• Geriatric:

  • Higher incidence of ANCA-associated vasculitis and anti-GBM disease: Often with more severe presentations and comorbidities.
  • Atypical Presentations: May present with non-specific symptoms, making diagnosis challenging.
  • Increased Risk of Complications: From AKI, fluid overload, and immunosuppressive therapy (infections, cardiovascular events, bone marrow suppression).
  • Polypharmacy: Potential for drug-drug interactions.
  • Reduced Functional Reserve: May tolerate therapies less well. Careful consideration of risks vs. benefits of aggressive immunosuppression.

• Pregnancy:

  • Diagnosis Challenges: Hypertension and proteinuria can be confounding, mimicking pre-eclampsia. Differentiating requires careful evaluation, including urinary sediment and other serologies.
  • Disease Activity: Some GNs (e.g., lupus nephritis) can flare during pregnancy or postpartum.
  • Therapeutic Challenges: Many immunosuppressive drugs are teratogenic or carry risks during pregnancy (e.g., cyclophosphamide, MMF are contraindicated; prednisone, azathioprine are relatively safer). Careful planning with multidisciplinary team is crucial.
  • Fetal Monitoring: For growth restriction and prematurity.

• Comorbidities:

  • Diabetes Mellitus: Can complicate diagnosis (diabetic nephropathy can cause proteinuria) and management. Patients with diabetes and nephritic syndrome are at higher risk of progression to ESKD.
  • Cardiovascular Disease: Common in patients with CKD and hypertension. Requires aggressive management of lipids, BP, and antiplatelet therapy.
  • Infections: Immunosuppression increases risk of severe infections. Prophylactic antibiotics (e.g., trimethoprim/sulfamethoxazole for PCP) may be indicated.
  • Liver Disease: Hepatitis B/C can cause specific GNs; liver dysfunction may affect drug metabolism.

Clinical Pearls

• Diagnostic:

  • "Cola-colored urine" + edema + hypertension = Think nephritic syndrome!
  • Red blood cell casts are pathognomonic for glomerulonephritis. Always check for them on urinalysis.
  • Rapidly progressive symptoms (days to weeks) demand urgent attention. Rule out RPGN immediately with biopsy.
  • Always look for systemic disease. Nephritic syndrome is often a renal manifestation of a systemic illness.
  • Don't delay renal biopsy if RPGN is suspected. Every day matters for renal recovery.

• Treatment:

  • Supportive care is paramount for all forms of nephritic syndrome (BP, fluid, electrolytes).
  • Immunosuppression must be tailored to the specific histological diagnosis and disease severity, not just the clinical syndrome.
  • Educate patients on medication side effects (especially corticosteroids) and the importance of adherence.
  • Monitor for infection in immunosuppressed patients.
  • ACE inhibitors/ARBs are renoprotective in the setting of proteinuria and should be used cautiously in acute AKI.

• Pitfalls:

  • Misattributing hematuria to a UTI or stones: Always examine urine for dysmorphic RBCs and casts, and quantify proteinuria.
  • Underestimating the severity of AKI: Small changes in creatinine can represent large declines in GFR.
  • Delaying kidney biopsy: Especially in RPGN, irreversible damage can occur quickly.
  • Overlooking systemic symptoms: Failure to identify underlying systemic disease can lead to inappropriate or delayed therapy.
  • Aggressive fluid administration: Can worsen fluid overload in oliguric patients.

Recent Updates

• Guidelines:

  • KDIGO (Kidney Disease: Improving Global Outcomes) guidelines for various glomerulonephritides (e.g., Glomerular Diseases Guideline, Lupus Nephritis Guideline). Updated recommendations emphasize personalized medicine, risk stratification, and specific targets for proteinuria and blood pressure.
  • EULAR/ERA-EDTA recommendations for the management of lupus nephritis and ANCA-associated vasculitides providing updated guidance on immunosuppressive regimens, including the role of rituximab and calcineurin inhibitors.

• Evidence:

  • Increased use of Rituximab: Strong evidence supporting its use for induction and maintenance in ANCA-associated vasculitis (e.g., RAVE, RITUXVAS trials) and increasingly for lupus nephritis (e.g., LUNAR trial, but more positive real-world experience).
  • Emerging therapies for Lupus Nephritis: Voclosporin (a novel calcineurin inhibitor) has received approval for lupus nephritis in combination with MMF and corticosteroids, showing improved renal response rates (AURORA trials). Belimumab (B-cell activating factor inhibitor) is also being evaluated for lupus nephritis.
  • C3 Glomerulopathy: Better understanding and classification of C3 glomerulopathies, with ongoing research into complement-targeted therapies (e.g., eculizumab for dense deposit disease/C3 glomerulonephritis in selected cases).
  • Precision Medicine: Growing interest in using biomarkers and genetic profiling to tailor treatment approaches for specific glomerulonephritides.

• Controversies:

  • Optimal duration and intensity of immunosuppression: Balancing efficacy against long-term side effects.
  • Role of corticosteroid-free regimens: Efforts to reduce corticosteroid burden, especially in ANCA-associated vasculitis and lupus nephritis, using alternatives like rituximab or novel agents.
  • Management of IgA Nephropathy: The role of tonsillectomy, and the specific indications and duration for corticosteroid use remain areas of debate, particularly with ongoing trials exploring novel approaches.
  • Value of repeat kidney biopsy: To assess response to therapy or guide changes in management, especially in chronic or refractory cases.

Key References

• Guidelines:

  • Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guidelines:
    • KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int 2021;100(4S):S1-S276.
    • KDIGO 2012 Clinical Practice Guideline for Glomerulonephritis. Kidney Int Suppl 2012;2(2):139-274.
    • KDIGO 2024 Clinical Practice Guideline for the Management of Lupus Nephritis (forthcoming).
  • European League Against Rheumatism (EULAR) / European Renal Association–European Dialysis and Transplant Association (ERA–EDTA) Recommendations:
    • Fanouriakis A, et al. 2019 EULAR/ACR points to consider for the diagnosis and management of neuropsychiatric lupus. Ann Rheum Dis 2021;80(11):1391-1402. (Relevant for SLE)
    • Yates M, et al. EULAR/ERA recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis 2022;81(12):1662-1673.

• Studies:

  • Jayne DR, et al. Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis. N Engl J Med 2010;363(3):211-220 (RAVE trial).
  • Rovin BH, et al. Efficacy and Safety of Voclosporin Versus Placebo for Lupus Nephritis (AURORA 1): A Phase 3, Randomised, Double-Blind, Placebo-Controlled Trial. Lancet 2021;397(10289):2070-2081.
  • Houssiau FA, et al. Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis: A Randomized Trial. Kidney Int 2010;77(7):617-625 (Euro-Lupus Nephritis Trial).

• Reviews:

  • Glassock RJ, et al. The Glomerulopathies. In: Taal MW, Chertow GM, Marsden PA, Skorecki K, Yu ASL, Brenner BM, eds. Brenner and Rector's The Kidney. 11th ed. Elsevier; 2020: Chapter 27.
  • Sethna CB, et al. Poststreptococcal glomerulonephritis. J Am Soc Nephrol 2011;22(2):224-230.
  • Kidney biopsy atlas from Kidney International and JASN.

---